Source: European Parliament
Priority question for written answer P-001539/2025
to the Commission
Rule 144
Laurent Castillo (PPE)
Over the course of 10 years, the EU has more than tripled the value of its pharmaceutical exports, generating a positive trade balance of EUR 193.6 billion in 2024. That year, 38 % of European pharmaceutical exports were to the US.
Although these figures show the high added value of pharmaceuticals manufactured in the EU, the US’ imposition of tariffs could damage that industry.
The 90-day suspension of tariffs for the EU has done nothing to alleviate the 145 % levy on China, and the EU depends on Asia for almost 80% of the active ingredients it needs for the production of its finished products.
In the light of the above, I ask the Commission:
- 1.If they are composed of active ingredients from China, will finished pharmaceutical products manufactured in the EU be subject, in whole or in part, to tariffs of 125 %?
- 2.Will the same be true for other manufacturing sectors, such as the automotive and technology sectors?
Submitted: 15.4.2025